Currently, concerning AD and other similar neurodegenerative disorders, the main treatment strategies are based on adjusting neurotransmission activity, including acetylcholinesterase inhibition as an attempt to increase cholinergic efficacy (Hung and Fu, 2017). This evidence concerns the gene ACHE and Alzheimer disease.